CNS Pharmaceuticals (CNSP) Stock: Buy, Sell, or Hold?
CNSP - CNS Pharmaceuticals, Inc. Common Stock
$5.84
0.09 (1.57%)
â˛
5d:
-0.79%
30d:
+16.57%
90d:
+23.73%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CNSP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CNSP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CNSP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CNSP is currently trading at $5.84, which is considered slightly high relative to its 30-day fair value range of $5.34 to $5.92.
Technical Outlook: Technically, CNSP is in a uptrend. The price is approaching resistance at $6.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CNSP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+71.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNSP is in a uptrend. The price is approaching resistance at $6.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CNSP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+71.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.34 -
$5.92
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 71.2% below Wall St target ($10.00)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.34 -
$5.92
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.48
Resistance Level
$6.01
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.52
Wall Street Target
$10.00
(+71.2%)
Share & Embed Analysis
Last updated: September 12, 2026 3:11 PM ET
Data refreshes hourly during market hours. Next update: 4:11 PM
Data refreshes hourly during market hours. Next update: 4:11 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNSP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
